These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

136 related items for PubMed ID: 3158448

  • 1. Medroxyprogesterone acetate (MAP) and tamoxifen (TMX) plasma levels after simultaneous treatment with 'low' TMX and 'high' MAP doses.
    Camaggi CM, Strocchi E, Canova N, Costanti B, Pannuti F.
    Cancer Chemother Pharmacol; 1985; 14(3):229-31. PubMed ID: 3158448
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Tamoxifen metabolism is altered by simultaneous administration of medroxyprogesterone acetate in breast cancer patients.
    Reid AD, Horobin JM, Newman EL, Preece PE.
    Breast Cancer Res Treat; 1992; 22(2):153-6. PubMed ID: 1391980
    [Abstract] [Full Text] [Related]

  • 4. Clinical trial of combined hormone therapy (MAP + TAM) for metastatic breast cancer.
    Pannuti F, Martoni A, Piana E, Tomasi L, Grieco A, Farris A, Saccani F, Baroni M.
    Chemioterapia; 1984 Aug; 3(4):211-5. PubMed ID: 6241846
    [Abstract] [Full Text] [Related]

  • 5. Effects of tamoxifen, estradiol benzoate and medroxyprogesterone acetate on the growth of DMBA-induced rat mammary carcinoma.
    Zanardi S, De Menech R, Pino G, Guarneri D, Dandolo G, Sanguineti M, Moro MG, Barbi GP, Paganuzzi M, Boccardo F.
    Chemioterapia; 1985 Jun; 4(3):239-42. PubMed ID: 3161642
    [Abstract] [Full Text] [Related]

  • 6. Sequential alternate administration of tamoxifen and medroxyprogesterone acetate in advanced breast cancer: clinical-biological randomized study.
    De Lena M, Tommasi S, Schittulli F, Lorusso V, Paradiso A.
    Tumori; 1990 Apr 30; 76(2):190-5. PubMed ID: 2139523
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Cyclic and sequential therapy with tamoxifen and medroxyprogesterone acetate in metastatic breast cancer.
    Nemoto T, Patel JK, Rosner D, Dao TL, Halvorson H.
    J Surg Oncol; 1989 Aug 30; 41(4):226-9. PubMed ID: 2526907
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Cyclical use of tamoxifen and high-dose medroxyprogesterone acetate in advanced estrogen receptor positive breast cancer.
    Gundersen S, Kvinnsland S, Lundgren S, Klepp O, Lund E, Børmer O, Høst H.
    Breast Cancer Res Treat; 1990 Nov 30; 17(1):45-50. PubMed ID: 2151369
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Alternating sequential endocrine therapy: tamoxifen and medroxyprogesterone acetate versus tamoxifen in postmenopausal advanced breast cancer patients.
    Beltrán M, Alonso MC, Ojeda MB, Izquierdo A, Ferrer J, Picó C, Anglada L, Catalán G, Batiste-Alentorn E, Tusquets I.
    Ann Oncol; 1991 Jul 30; 2(7):495-9. PubMed ID: 1832944
    [Abstract] [Full Text] [Related]

  • 13. [Hormonotherapy of metastatic breast cancer with tamoxifen and medroxyprogesterone acetate. Randomized trial comparing alternating sequences with successive applications].
    Mauriac L, Durand M, Bonichon F, Chauvergne J.
    Bull Cancer; 1986 Jul 30; 73(2):148-54. PubMed ID: 2942203
    [Abstract] [Full Text] [Related]

  • 14. New trends in the use of medroxyprogesterone acetate as a chemotherapeutic agent in gynecologic malignancies.
    Vanderstappen D, Bonte J.
    Eur J Gynaecol Oncol; 1992 Jul 30; 13(2):113-23. PubMed ID: 1534051
    [Abstract] [Full Text] [Related]

  • 15. [Estrogen antagonists and inhibitors in hormone therapy of breast cancer].
    Dryzhak VI.
    Vopr Onkol; 1989 Jul 30; 35(7):771-8. PubMed ID: 2528239
    [No Abstract] [Full Text] [Related]

  • 16. Modalities and results of a combined anti-estrogenic therapy by means of tamoxifen and medroxyprogesterone in gynecologic cancerology.
    Bonte J, Janssens JP, Ide P.
    Eur J Gynaecol Oncol; 1986 Jul 30; 7(1):45-50. PubMed ID: 2938955
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Chemotherapy versus chemotherapy plus hormonotherapy in postmenopausal advanced breast cancer patients. A randomized trial.
    Viladiu P, Alonso MC, Avella A, Beltrán M, Borrás J, Ojeda B, Bosch FX.
    Cancer; 1985 Dec 15; 56(12):2745-50. PubMed ID: 3902200
    [Abstract] [Full Text] [Related]

  • 19. [Results of tamoxifen-medroxyprogesterone acetate sequential therapy in 22 patients with recurrent breast cancer].
    Noguchi S, Yamamoto H, Inaii H, Koyama H.
    Gan To Kagaku Ryoho; 1989 Nov 15; 16(11):3555-8. PubMed ID: 2530936
    [Abstract] [Full Text] [Related]

  • 20. Medroxyprogesterone acetate (MAP) plasma levels after simultaneous oral and intramuscular administration in cancer patients.
    Pannuti F, Camaggi CM, Strocchi E, Giovannini M, Canova N, Murari G.
    Cancer Chemother Pharmacol; 1982 Nov 15; 9(2):122-3. PubMed ID: 6216987
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.